Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

University of Ottawa

$25,000.00

Chemical synthesis and rationale design of novel peptide and nonpeptide based small molecule inhibitors of SKI-1

EF 2013-14

Résumé
Subtilisin Kexin Isozyme-1 (SKI-1) also known as Site1Protease (S1P) is a proteolytic enzyme found within cellular compartments of various tissues of mammalian systems, including human. This enzyme cleaves larger, inactive protein molecules at specific sites, to generate functionally active smaller protein forms that play important roles in various health conditions and diseases, including viral infections and cholesterol synthesis. In all cases, an increase in enzyme activity of SKI-1 results in the formation of a higher level of biologically active cleaved product/s that eventually contribute to the initiation or progression of the disease. One way of managing the disease will be to lower down the activity of the enzyme via the application of chemical agents that interact and bind with the enzyme, thereby blocking its activity. In fact this approach has been applied for intervention of many diseases including cardiovascular diseases, hypertension, arthritis, asthma and AIDS. For more than a decade, our laboratory has been engaged in studying structure, function and activity of several enzymes including SKI-1. In this proposal we intend to develop compounds that are capable of inhibiting the ability of the SKI-1 enzyme to cleave large inactive proteins to their small functionally active forms. Thus, we will prepare several SKI-1 inhibitory compounds based on various strategies which can inactivate SKI-1 and make it less efficient in cutting large proteins. In theory these compounds are expected to find important applications, not only to study the function of the enzyme, but also in therapeutic interventions of diseases such as viral infections, hypercholesterolemia etc. This research will therefore contribute to a better understanding of the importance of SKI-1 in above diseases and could lead to novel compounds with important therapeutic values.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
238547-2009
Name nom
Basak, Ajoy
Department département
Medicine, Faculty of
Organization id
28
Institution établissement
University of Ottawa
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2009
Award amount
25000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
32
Committee name en
Cell Biology
Committee name fr
Biologie cellulaire
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5403
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Proteins and peptides, amino acids
Research subject fr
Protéines et peptides, acides aminés
Partie
5
Nb partie
5
Application title
Chemical synthesis and rationale design of novel peptide and nonpeptide based small molecule inhibitors of SKI-1
Keyword
NSERC
Application summary
Subtilisin Kexin Isozyme-1 (SKI-1) also known as Site1Protease (S1P) is a proteolytic enzyme found within cellular compartments of various tissues of mammalian systems, including human. This enzyme cleaves larger, inactive protein molecules at specific sites, to generate functionally active smaller protein forms that play important roles in various health conditions and diseases, including viral infections and cholesterol synthesis. In all cases, an increase in enzyme activity of SKI-1 results in the formation of a higher level of biologically active cleaved product/s that eventually contribute to the initiation or progression of the disease. One way of managing the disease will be to lower down the activity of the enzyme via the application of chemical agents that interact and bind with the enzyme, thereby blocking its activity. In fact this approach has been applied for intervention of many diseases including cardiovascular diseases, hypertension, arthritis, asthma and AIDS. For more than a decade, our laboratory has been engaged in studying structure, function and activity of several enzymes including SKI-1. In this proposal we intend to develop compounds that are capable of inhibiting the ability of the SKI-1 enzyme to cleave large inactive proteins to their small functionally active forms. Thus, we will prepare several SKI-1 inhibitory compounds based on various strategies which can inactivate SKI-1 and make it less efficient in cutting large proteins. In theory these compounds are expected to find important applications, not only to study the function of the enzyme, but also in therapeutic interventions of diseases such as viral infections, hypercholesterolemia etc. This research will therefore contribute to a better understanding of the importance of SKI-1 in above diseases and could lead to novel compounds with important therapeutic values.